However, when we carried multivariate analysis, patients with grade 1 tumor had 12.39-fold higher odds of positive ANGPTL4 expression than those with grade 3 tumors after adjustment for all other clinicopathological characteristics (adjusted OR = 12.39, p = 0.040), this is in contrast to Shafiq et al.’s findings where ANGPTL4 mRNA transcript and serum levels were significantly higher in high grade breast carcinoma samples compared to low grade and control samples. The gene discussed is ANGPTL4; the disease is breast carcinoma.